Bartlett & CO. Wealth Management LLC Lowers Position in Becton, Dickinson and Company $BDX

Key Points

• Bartlett & CO. Wealth Management LLC reduced its stake in Becton, Dickinson and Company by 5.3%, owning 33,779 shares valued at approximately $5.8 million after selling 1,881 shares in Q2.
• Insider transactions revealed that Claire Fraser, a Director, sold 917 shares for $171,937.50, reflecting a 3.96% decrease in her position.
• Several analysts have upgraded or adjusted their target prices for Becton, Dickinson and Company, with a consensus rating of "Hold" and an average price target of $205.40.

Bartlett & CO. Wealth Management LLC trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 5.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 33,779 shares of the medical instruments supplier's stock after selling 1,881 shares during the period. Bartlett & CO. Wealth Management LLC's holdings in Becton, Dickinson and Company were worth $5,818,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Saudi Central Bank purchased a new stake in shares of Becton, Dickinson and Company in the first quarter worth about $26,000. Smallwood Wealth Investment Management LLC bought a new stake in Becton, Dickinson and Company in the 1st quarter worth approximately $27,000. Alpine Bank Wealth Management purchased a new position in shares of Becton, Dickinson and Company in the first quarter valued at $29,000. Cornerstone Planning Group LLC increased its position in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA bought a new stake in Becton, Dickinson and Company in the first quarter worth $31,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the company's stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock valued at $562,036 in the last ninety days. Corporate insiders own 0.36% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Barclays decreased their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 3rd. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a report on Thursday, September 25th. They issued a "sector perform" rating and a $211.00 target price for the company. Finally, Argus raised their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of "Hold" and an average price target of $205.40.

Becton, Dickinson and Company Stock Up 1.7%

Shares of NYSE BDX opened at $187.06 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The stock has a 50 day moving average price of $188.55 and a 200 day moving average price of $188.18. The firm has a market capitalization of $53.62 billion, a price-to-earnings ratio of 33.64, a PEG ratio of 1.48 and a beta of 0.27. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.Becton, Dickinson and Company's revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the company posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is presently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.